Medicaid to Cover Endari for Sickle Cell Disease in the U.S. | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Medicaid to Cover Endari for Sickle Cell Disease in the U.S.


Emmaus Life Sciences has reached an agreement with the Centers for Medicare and Medicaid Services that will allow coverage of Endari (L-glutamine oral powder) to reduce acute complications of sickle cell disease (SCD) in adults and children 5 years and older.

“This treatment is considered very important by many providers and patients because of its excellent safety profile and the evidence of effectiveness from the Phase III study that showed a reduction in acute chest syndrome, decreased occurrence of sickle crises and decreased frequency of hospitalizations in the Endari group compared to the placebo group,” Yutaka Niihara, MD, MPH, chairman and CEO of Emmaus, said in a press release. “Having the Medicaid Drug Rebate Program in place will make Endari more accessible to patients who need it most.”

https://www.onescdvoice.com/wp-content/uploads/2018/02/Emmaus.jpg